Examiner: GAUGER, PAUL RANDALL

Tech Center 1600 • Art Units: 1626 1629

This examiner grants 57% of resolved cases

Performance Statistics

57.1%

Allow Rate

-2.9% vs TC avg

Total Applications

-7.9%

Interview Lift

1230

Avg Prosecution Days

Based on 21 resolved cases, 2023–2026

1.1%

§101 Eligibility

19.2%

§102 Novelty

30.9%

§103 Obviousness

22.3%

§112 Clarity

App #	Title	Status	Assignee
17774002	SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF	Final Rejection	DANA-FARBER CANCER INSTITUTE, INC.
18454315	BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION	Non-Final OA	Hoffmann-La Roche Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.